BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Australia

WuXi XDC H1 2026 Revenue Jumps 37% to RMB 3.7 Bn on Strong Bioconjugate Demand

Group total revenue increased to RMB 3,701.4 million, representing 37.0% period-over-period growth on an AER[1] basis (41.5% growth on a CER[2]...

August 26, 2026 | Company results

Antengene’s ATG-201 Wins Australian Clearance for Phase I Autoimmune Disease Trial

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, develop...

August 26, 2026 | News

CureGene Doses First Subject in Australia Phase I Trial of Oral Metabolic Drug CG-0416

CureGene recently announced that the first subject has been dosed in its Phase I clinical trial of CG-0416, a novel oral liver-targeting THR-β agonist...

August 24, 2026 | News

ArkBio’s Long-Acting Influenza Candidate AK0406 Secures IND Approval in China

Shanghai Ark Biopharmaceutical Co., Ltd. announced that the Investigational New Drug (IND) application for AK0406 injection, the company's first long-actin...

August 14, 2026 | News

Australians Warned Against Buying Unregulated Health Supplements from Overseas

With longevity science gaining global attention and new products rapidly entering the market, overseas supplement retailers are increasingly targeting Aust...

August 06, 2026 | News

IMPACT Therapeutics Partners with Pharmanovia to Commercialise Senaparib Across Europe, MENA, Australia and New Zealand

IMPACT Therapeutics ("IMPACT") (07630.HK) is pleased to announce that it has entered into an exclusive partnership (the "Exclusive Partnership") with Pharm...

August 03, 2026 | News

7 Countries Competing to Be the Region’s Next Biomanufacturing Hub

A siting decision for a biomanufacturing facility is one of the most expensive commitments a company makes, and it is made against a fifteen to twenty year...

July 27, 2026 | Analysis

ArkBio Completes Dosing in Phase I Trial of Long-Acting Influenza Prevention Candidate AK0406

Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that all cohorts of healthy volunteers have been dosed in an Australian Phase I trial w...

July 27, 2026 | News

Menarini Asia-Pacific, Pharmacosmos Partner to Expand Cosela® Access Across APAC

Menarini Asia-Pacific announced an exclusive partnership with Pharmacosmos A/S to register, commercialise and distribute Cosela® (trilaciclib) acr...

July 23, 2026 | News

Dimerix Acquires Phase II-Ready DMX-652 to Expand Kidney Disease Pipeline

Dimerix acquires Phase 2-ready asset, DMX-652 - with potential for rapid advancement into a Phase 2 clinical study under an open US Investigational New D...

July 20, 2026 | News

Neurizon Completes Rapid Phase II/III NUZ-001 Enrolment for ALS with Results Expected in Q2 2027

250 participants enrolled in less than five months from first participant dosing, representing the fastest site activation and enrolment in the HEALEY AL...

July 20, 2026 | News

Telix Takes Next-Generation PSMA Radioligand Therapy into Earlier Prostate Cancer Treatment

First patients dosed in OPTIMAL-e[1] Phase 2 study evaluating TLX597-Tx for metastatic hormone-sensitive prostate cancer at St Vincent's Hospital Sy...

July 17, 2026 | News

Australia Builds a New Radiopharmaceutical Gateway from Research to Patient Care

First-of-its-kind facility in Australia where radiopharmaceuticals are developed, manufactured and administered to patients under one roof. Patient care...

July 17, 2026 | News

Delonix Bioworks Doses First Participant in China Phase 1 Trial of Next-Generation MenB Vaccine DX-104

Delonix Bioworks, a clinical-stage biotechnology company pioneering genetically engineered bacterial vaccines, announced that the first participant has bee...

July 15, 2026 | News

Stay Connected